Psychotropic Drug Prescription Patterns and Their Predictors among Older Adult Patients with Schizophrenia in a Tertiary-referral Psychiatric Hospital

10.4103/tpsy.tpsy_16_21

Mu-Chun Lin；Hsing-Kang Chen

antipsychotic polypharmacy ； clozapine ； mood stabilizer ； Research on Asian Psychotropic Prescription Pattern

台灣精神醫學

35卷2期（2021 / 06 / 01）

70 - 75

英文

Objective: Medical treatments for patients with refractory schizophrenia can be roughly divided into three strategies - clozapine administration, adjuvant use of mood stabilizers, and antipsychotic polypharmacy. Few studies exist on older adult patients with schizophrenia. In this study, we intended to assess the prevalence of clozapine administration, adjuvant use of mood stabilizers, and antipsychotic polypharmacy, and to find their predictors in those patients with schizophrenia. Methods: In this cross-sectional study, we collected information of patients' sociodemographic and clinical details. Their psychotic symptoms were evaluated using a clinical interview with a positive and negative syndrome scale (PANSS). Results: We enrolled 240 study participants, with 74 patients (30.8%) receiving clozapine, 40 patients (16.7%) receiving adjuvant use of mood stabilizers, and 42 patients (17.5%) receiving antipsychotic polypharmacy. Younger age (p ＜ 0.05), higher PANSS general symptoms subscales (p ＜ 0.001), and higher dosage of antipsychotics (p ＜ 0.01) were significantly related to patients with clozapine administration. As to patients with adjuvant therapy with mood stabilizers, only younger age (p ＜ 0.01) and male gender (p ＜ 0.05) showed significant association. Finally, patients receiving antipsychotic polypharmacy were significantly related to lower body mass index (BMI) (p ＜ 0.05), higher PANSS positive symptoms subscale (p ＜ 0.05), and higher dosage of antipsychotics (p ＜ 0.001). Conclusions: Our findings showed that patients with clozapine prescription were 30.8% in prevalence which is higher than other studies in Asia. The prevalence of adjuvant mood stabilizers and antipsychotic polypharmacy were 16.7% and 17.5%, respectively. Those two findings are lower than those in other studies in Asia.

1. Aizenberg, D,Sigler, M,Weizman, A(2002).Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case-control study.Int Psychogeriatr,14,307-310.
2. Anstey, KJ,von Sanden, C,Luszcz, MA(2006).An 8-year prospective study of the relationship between cognitive performance and falling in very old adults.J Am Geriatr Soc,54,1169-1176.
3. Beuscart, JB,Dupont, C,Defebvre, MM(2014).Potentially inappropriatemedications (PIMs) and anticholinergic levels in the elderly: a population based study in a French region.Arch Gerontol Geriatr,59,630-635.
4. Bhugra, D(2006).Severe mental illness across cultures.Acta Psychiatr Scand Suppl,113,17-23.
5. Cancelli, I,Gigli, GL,Piani, A(2008).Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: a population-based study.J Clin Psychopharmacol,28,654-659.
6. Chen, WC,Wang, JD,Lew-Ting, CY(2007).Workplace violence on workers caring for long-term institutionalized schizophrenic patients in Taiwan.J Occup Health,49,311-316.
7. Chong, MY,Tan, CH,Fujii, S(2004).Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change.Psychiatry Clin Neurosci,58,61-67.
8. Citrome, L,Levine, J,Allingham, B(2000).Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998.Psychiatr Serv,51,634-638.
9. Dauphinot, V,Faure, R,Omrani, S(2014).Exposure to anticholinergic and sedative drugs, risk of falls, and mortality: an elderly inpatient, multicenter cohort.J Clin Psychopharmacol,34,565-570.
10. Davidson, M,Harvey, PD,Powchik, P(1995).Severity of symptoms in chronically institutionalized geriatric schizophrenic patients.Am J Psychiatry,152,197-207.
11. Dong, M,Zeng, LN,Zhang, Q(2019).Antipsychotic polypharmacy in older adult Asian patients with schizophrenia: research on Asian Psychotropic Prescription Pattern.J Geriatr Psychiatry Neurol,32,304-311.
12. Dong, M,Zeng, LN,Zhang, Q(2019).Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey.Asian J Psychiatr,45,74-80.
13. Faden, J,Citrome, L(2019).Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment.Expert Opin Pharmacother,20,11-24.
14. Fassino, S,Amianto, F,Gastaldo, L(2009).Anger and functioning amongst inpatients with schizophrenia or schizoaffective disorder living in a therapeutic community.Psychiatry Clin Neurosci,63,186-194.
15. Fenton, WS,McGlashan, TH,Victor, BJ(1997).Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders.Am J Psychiatry,154,199-204.
16. Gallego, JA,Bonetti, J,Zhang, J(2012).Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.Schizophr Res,138,18-28.
17. Ganguly, R,Kotzan, JA,Miller, LS(2004).Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.J Clin Psychiatry,65,1377-1388.
18. Gören, JL,Meterko, M,Williams, S(2013).Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia.Psychiatr Serv,64,527-533.
19. Hennekens, CH,Hennekens, AR,Hollar, D(2005).Schizophrenia and increased risks of cardiovascular disease.Am Heart J,150,1115-1121.
20. Jager, M,Riedel, M,Obermeier, M(2010).Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patients.Schizophr Res,118,183-188.
21. Kane, J,Honigfeld, G,Singer, J(1988).Clozapine for the treatment-resistant schizophrenic. a double-blind comparison with chlorpromazine.Arch Gen Psychiatry,45,789-796.
22. Kane, JM(1992).Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview.Br J Psychiatry Suppl,17,41-45.
23. Kay, SR,Fiszbein, A,Opler, LA(1987).The positive and negative syndrome scale (PANSS) for schizophrenia.Schizophr Bull,13,261-276.
24. Kohen, I,Lester, PE,Lam, S(2010).Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole.Neuropsychiatr Dis Treat,6,47-58.
25. Kreyenbuhl, J,Valenstein, M,McCarthy, JF(2006).Long-term combination antipsychotic treatment in VA patients with schizophrenia.Schizophr Res,84,90-99.
26. Landi, F,Dell’Aquila, G,Collamati, A(2014).Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home.J Am Med Dir Assoc,15,825-829.
27. Lieberman, JA,Stroup, TS,McEvoy, JP(2005).Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.N Engl J Med,353,1209-1223.
28. Meyers, BS,Jeste, DV(2010).Geriatric psychopharmacology: evolution of a discipline.J Clin Psychiatry,71,1416-1424.
29. Nielsen, J,Røge, R,Schjerning, O(2012).Geographical and temporal variations in clozapine prescription for schizophrenia.Eur Neuropsychopharmacol,22,818-824.
30. Remington, G,Saha, A,Chong, SA(2005).Augmentation strategies in clozapine-resistant schizophrenia.CNS Drugs,19,843-872.
31. Saha, S,Chant, D,Welham, J(2005).A systematic review of the prevalence of schizophrenia.PLoS Med,2,e141.
32. Sim, K,Su, A,Fujii, S(2004).Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.Br J Clin Pharmacol,58,178-183.
33. Suzuki, T,Uchida, H,Takeuchi, H(2009).Augmentation of atypical antipsychotics with valproic acid. an open-label study for most difficult patients with schizophrenia.Hum Psychopharmacol,24,628-638.
34. Tor, PC,Ng, TP,Yong, KH(2011).Adjunctive benzodiazepine treatment of hospitalized schizophrenia patients in Asia from 2001 to 2008.Int J Neuropsychopharmacol,14,735-745.
35. Uchida, H,Pollock, BG,Bies, RR(2009).Predicting age-specific dosing of antipsychotics.Clin Pharmacol Ther,86,360-362.
36. Wahlbeck, K,Cheine, M,Essali, MA(2000).Clozapine versus typical neuroleptic medication for schizophrenia.Cochrane Database Syst Rev,2,CD000059.
37. Wang, SP,Wang, JD,Chang, JH(2020).Symptomatic remission affects employment outcomes in schizophrenia patients.BMC Psychiatry,20,219.
38. Weich, S,Pearce, HL,Croft, P(2014).Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study.Br Med J,348,g1996.
39. Woods, SW(2003).Chlorpromazine equivalent doses for the newer atypical antipsychotics.J Clin Psychiatry,64,663-667.
40. Wu, BY,Wu, BJ,Lee, SM(2014).Prevalence and associated factors of comorbid skin diseases in patients with schizophrenia: a clinical survey and national health database study.Gen Hosp Psychiatry,36,415-421.
41. Xiang, YT,Buchanan, RW,Ungvari, GS(2013).Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009.PLoS One,8,e66154.
42. Xiang, YT,Dickerson, F,Kreyenbuhl, J(2013).Common use of anticholinergic medications in older patients with schizophrenia: findings of the Research on Asian Psychotropic Prescription Pattern (REAP) study, 2001-2009.Int J Geriatr Psychiatry,28,305-311.
43. Xiang, YT,Dickerson, F,Kreyenbuhl, J(2012).Common use of antipsychotic polypharmacy in older Asian patients with schizophrenia (2001-2009).J Clin Psychopharmacol,32,809-813.
44. Xiang, YT,Dickerson, F,Kreyenbuhl, J(2012).Adjunctive mood stabilizer and benzodiazepine use in older Asian patients with schizophrenia, 2001-2009.Pharmacopsychiatry,45,217-222.
45. Xiang, YT,Wang, CY,Si, TM(2011).Use of anticholinergic drugs in patients with schizophrenia in Asia from 2001 to 2009.Pharmacopsychiatry,44,114-118.
46. Xiu, MH,Hui, L,Dang, YF(2009).Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics.Prog Neuropsychopharmacol Biol Psychiatry,33,1508-1512.
47. Xu, SW,Dong, M,Zhang, Q(2020).Clozapine prescription pattern in patients with schizophrenia in Asia: the REAP survey (2016).Psychiatry Res,287,112271.
48. Yang, SY,Chen, LY,Najoan, E(2018).Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: fourth survey of Research on Asian Prescription Patterns on antipsychotics.Psychiatry Clin Neurosci,72,572-579.